tirzepatide for fatty liver Ever-Rising Disease Gets Its First Drug and a New Name Tirzepatide: A Game-Changer for MASH

Similar content being viewed by others Log in or create a free account to read this content Gain free access to this article, as well as selected content from this journal and more on nature.com or Data availability All data generated and analyzed for this study were included in the study

placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in PYC today announced that we have initiated a global repeat dose study of PYC-001 in patients with ADOA (known as the MYRTLE study) and that the first subject in this clinical trial has now received their initial dose of PYC-001 - The objective of the MYRTLE study is to evaluate the safety/tolerability and efficacy profile of repeat dosing of PYC-001 in the ADOA population with a view to establishing clinical proof of concept for the drug candidate prior to initiation of a registrational study - Data from the Myrtle study across both safety/tolerability and efficacy endpoints is expected to be available in H2 2026 Read the full announcement here: To view or add a comment, sign in First new therapy for IPF in over 10 years

2016;11(1):e0146439

Aloe Vera Extract: A healing and cooling ingredient